StimuCal™, the patent-pending, concentrated source of natural calcium with bone-stimulating protein from Waitaki Bioscience, is now available to manufacturers looking for a safe, high-quality ingredient with proven benefits for bone mineralization.
Most calcium supplements these days are designed to be rapidly absorbed. However, a number of leading researchers have identified a link between calcium supplementation and an increased risk of heart attack, which is thought to be directly related to the rapid spiking of blood calcium levels following ingestion of the supplement.
StimuCal is different. Rigorously tested in an independently designed, randomized, placebo-controlled trial of 100 postmenopausal women conducted by the Department of Medicine at the University of Auckland, New Zealand, StimuCal was found to produce lower peak blood calcium levels than either calcium carbonate or calcium citrate while maintaining an identical effect on markers of bone turnover. The women were randomized to receive 1000 mg per day of calcium as either StimuCal, calcium carbonate, calcium citrate, or placebo. Acute changes in blood calcium levels were monitored over an 8-hour period and key biochemical markers of bone turnover were measured at baseline and at three months as a measure of efficacy. Peak blood calcium levels after ingestion of StimuCal were 45 percent to 49 percent lower than peak blood calcium levels after ingestion of the same amount of calcium from either calcium carbonate or calcium citrate.
“We are proud of StimuCal and the science that supports its safety and efficacy,” said Craig McIntosh, chief executive officer of Waitaki Biosciences. “After a significant product development phase, and successful clinical trial work, we are delighted to now be in a position to offer this product to the market and look forward to meeting with manufacturers at SupplySide West.”
To set an appointment please email Sue Finderup, product manager ([email protected]) or stop by SupplySide West booth #32136.